Results from Phase 2 Study of Galdermas Investigational Therapy Nemolizumab in Patients with Moderate to Severe Prurigo Nodularis

Results from Phase 2 Study of Galderma’s Investigational Therapy Nemolizumab in Patients with Moderate to Severe Prurigo Nodularis

09:52 EST 21 Feb 2020 | Speciality Pharma Journal

LAUSANNE, Switzerland–(BUSINESS WIRE)–Galderma today announced that The New England Journal of Medicine (NEJM) has published full results from the Phase 2 study of its investigational therapy nemolizumab in adult patients suffering from moderate-to-severe prurigo nodularis (PN). PN is a rare, potentially debilitating, chronic skin condition with thick skin nodules covering large body areas and associated …

More From BioPortfolio on "Results from Phase 2 Study of Galderma’s Investigational Therapy Nemolizumab in Patients with Moderate to Severe Prurigo Nodularis"